GlassScriptPhysician profile
Minh N Bui
NPI 1396811600
$895.46
in general payments reported to CMS, 2019-2025
23 companies · $84.59 in 2025
The $84.59 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $71.48 · 2020: $76.04 · 2021: $157 · 2022: $138 · 2023: $121 · 2024: $247 · 2025: $84.59.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $453.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $452.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $101.40 | 2024 | Watchman Flx, Bodyguardian |
| Inspire Medical Systems, INC. | $96.72 | 2023-2025 | Inspire |
| Atricure, INC. | $96.21 | 2021 | |
| Medtronic Vascular, INC. | $72.44 | 2019-2020 | |
| Cardiva Medical, INC. | $67.27 | 2020-2023 | Cardiva Vascade 6/7f Vcs |
| Pfizer INC. | $57.45 | 2021-2022 | |
| Impulse Dynamics (USA) INC. | $38.95 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $35.35 | 2025 | Uptravi, Opsumit |
| Abbott Laboratories | $34.90 | 2020-2023 | Diamondback Coronary |
| Astrazeneca Pharmaceuticals LP | $31.33 | 2021-2022 | |
| Lantheus Medical Imaging, INC. | $26.41 | 2023 | Definity |
| Kiniksa Pharmaceuticals, LTD. | $24.91 | 2021 | |
| Zoll Circulation INC | $24.88 | 2025 | Therox Ds2 Console, Catheter, Downstream Cartridge |
| Medicomp INC | $24.04 | 2024 | Telepatch Cardiac Monitor |
| Novo Nordisk INC | $23.28 | 2024 | Ozempic, Rybelsus |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $23.04 | 2024 | Arcalyst |
| Novartis Pharmaceuticals Corporation | $22.08 | 2024 | |
| Merck Sharp & Dohme LLC | $21.70 | 2022 | |
| Angiodynamics, INC. | $18.01 | 2023 | Alphavac |
| Terumo Medical Corporation | $14.80 | 2023 | Glidewire, Heartrail |
| Gilead Sciences, INC. | $14.32 | 2019 | |
| Sanofi-Aventis U.S. LLC | $14.10 | 2020 | |
| Abiomed | $11.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Minh Bui listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.